Kaya 959 Kaya Biz

Dis-Chem earnings jump as it shakes off Covid.

Loading player...
Pharmacy and healthcare retail group Dis-Chem says it is trading at pre-Covid levels in South Africa, with expansions and acquisitions boosting its reach and driving profitability. In its interim results for the six-month period ending 31 August 2022, Dis-Chem reported group revenue growth of 9.3% to R16.3 billion over the corresponding half-year period. Retail revenue grew by 9.3% to R14.4 billion, with comparable pharmacy store revenue at 3.6%. If the contribution of Covid-19 vaccines and testing are excluded from both periods, retail revenue grew by 10.0%. Headline earnings increased by an exceptional 44.3% over the prior corresponding period, with basic headline earnings per share (HEPS) at 70.3 cents – an increase of 44.3%.
2 Nov 2022 2PM English South Africa Business News · Investing

Other recent episodes

SA’s Draft AI Policy: The Cost of Getting It Wrong

Free SA spokesperson Gideon Joubert discusses the organization's concerns about South Africa’s Draft National AI Policy—including expanded bureaucracy, duplicated institutions, and barriers for startups.
21 Apr 4PM 5 min

Legal AI Time Bombs

Pinsent Masons’ Geoffrey Allsop explains why employers are already legally liable for AI‑driven decisions under South African law. We explore discrimination risks from foreign‑trained models and what the Draft AI Policy signals for workplace regulation.
21 Apr 4PM 9 min

Understanding SA’s Draft AI Policy

Werksmans’ Ahmore Burger‑Smidt unpacks South Africa’s Draft National AI Policy. This includes the proposed new AI institutions, privacy blind spots, and the implications for business.
21 Apr 4PM 21 min
All episodes